BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 23
• 26
• 27
• 28
• 29
• 30
• 31

• Press Releases

  QuidelOrtho to Participate in Upcoming June 2025 Investor Conferences

  May 23, 2025

   · 

  1 min read
• Press Releases

  Senti Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

  May 23, 2025

   · 

  3 min read
• Press Releases

  Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors

  May 23, 2025

   · 

  3 min read
• Press Releases

  Bio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025

  May 23, 2025

   · 

  1 min read
• Press Releases

  Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting

  May 23, 2025

   · 

  5 min read
• Press Releases

  PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

  May 23, 2025

   · 

  8 min read
• Press Releases

  Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025

  May 23, 2025

   · 

  10 min read
• Press Releases

  Menarini Group Presents Updated Data Underscoring the Combinability of Elacestrant (ORSERDU®) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2025 Annual Meeting

  May 23, 2025

   · 

  10 min read
• Press Releases

  Avidicure to Present Preclinical Data from Lead TROP2-targeting Multifunctional Antibody Program at the 2025 American Society of Clinical Oncology Annual Meeting

  May 23, 2025

   · 

  2 min read
• Press Releases

  Boehringer Ingelheim to present early clinical evidence of innate immune modulation and anti-tumor activity via SIRPα blockade in two ongoing trials at ASCO 2025

  May 23, 2025

   · 

  7 min read